$11.6m that I stated came from this:Please provide evidence of...

First 23 Last

Share
Profile

Follow
ThePig

3,168 Posts.

1781

12/06/25

11:45

Post #: 79404895
Share

Originally posted by dalts66: ↑

For someone who expects compliance with all i dotted and all Ts. crissed from a BOD, you surprise me how you accept mediocre research from yourself.

You were wrong when you stated your option fix when the CR was done. You were wrong when stating the amount they have in the bank now. Yet you still think your ideas are better than those running the company.

As has been explained to you many times, option money can not be relied upon until after the option expiry. Regardless of how far they are in the money. And that expiry date would be after the date the tax refund could be available. We need arms being dosed now. Without money, we can't do that. Without having arms dosed, the company can't build the share price. So your idea would mean that graph would continue as it is.
CHM is fast approaching a point where a partner comes on board. I find that an exciting opportunity. This could potentially happen before the calendar year end if we get the right data.
Dr Bec ensuring we are funded to achieve this seems like the right thing to me. As CHM is funded to plan and dose arms. Your idea would leave them waiting to see how much money they get as the option expiry date approaches. Greatly delaying the trial progress.

This doesn't seem like a very hard concept to understand. This is the very high risk end of the market. CHM has two major risks. One is finance, the other is the drug performance. Dr Bec and team have just done their best to mitigate the financial problem to some point after where the opportunity for a partner exists. I like that. The drug so far has shown promise.
So, the risk has finally swapped from being the dollars in the bank to drug performance. That's the best situation CHM has been in for many years.

Expand

$11.6m that I stated came from this:

Please provide evidence of my inaccurate 'option fix when the CR was done'.

CHM Price at posting: 0.4¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

IXR

Ionic Rare Earths falls -7% as momentum slips on vague production update

NUZ

Neurizon inks $1.5M loan against R&D Tax Rebate

HAR

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

First 23 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.4¢		Change 0.001(33.3%)		Mkt cap ! $12.99M

Open	High	Low	Value	Volume
0.3¢	0.4¢	0.3¢	$949	312.2K

Buyers (Bids)

No.	Vol.	Price($)
70	67782438	0.3¢

Sellers (Offers)

Price($)	Vol.	No.
0.4¢	91927011	27

View Market Depth

No.	Vol.	Price($)
70	67782438	0.003
26	26746044	0.002
13	54414000	0.001
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.004	91927011	27
0.005	33248062	21
0.006	17929018	21
0.007	6512518	7
0.008	7317101	5

Last trade - 16.10pm 30/07/2025 (20 minute delay)

CHM (ASX) Chart

$11.6m that I stated came from this:Please provide evidence of...

Ionic Rare Earths falls -7% as momentum slips on vague production update

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

$11.6m that I stated came from this:Please provide evidence of...

Top Stories

Ionic Rare Earths falls -7% as momentum slips on vague production update

Neurizon inks $1.5M loan against R&D Tax Rebate

Haranga jumps +7% on Lincoln acquisition

HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic

ASX Market Close: Index rebounds as investors buoyant | July 30, 2025

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News